Quarterly report pursuant to Section 13 or 15(d)

Grant Revenue (Details)

v3.20.2
Grant Revenue (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 07, 2020
Dec. 31, 2019
Oct. 31, 2017
May 31, 2017
Jun. 30, 2016
May 31, 2016
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Grant Revenue                    
Revenue             $ 849,732 $ 6,439 $ 2,344,777 $ 1,049,988
Maximum                    
Grant Revenue                    
Amount awarded from NIH grant $ 224,713                  
Pelican Therapeutics, Inc.                    
Grant Revenue                    
Amount awarded from CPRIT grant           $ 15,200,000        
Remaining grant amount             1,500,000   1,500,000  
Contribution to be made by Pelican             7,600,000   $ 7,600,000  
Pelican Therapeutics, Inc. | Maximum                    
Grant Revenue                    
Amount awarded from CPRIT grant         $ 15,200,000          
Royalty percentage after threshold is met                 1.00%  
Pelican Therapeutics, Inc. | Tranche I                    
Grant Revenue                    
Revenue       $ 1,800,000            
Pelican Therapeutics, Inc. | Tranche II                    
Grant Revenue                    
Revenue     $ 6,500,000              
Pelican Therapeutics, Inc. | Tranche III                    
Grant Revenue                    
Revenue   $ 5,400,000                
Pelican Therapeutics, Inc. | Grant revenue                    
Grant Revenue                    
Revenue                 $ 12,600,000  
Amount the company is required to match of each dollar of grant             0.50   0.50  
Threshold amount for match of grant             $ 1.00   $ 1.00